反流体征评估-10(RSA-10)的效度与信度研究
本研究开发并验证用于记录喉咽反流病(LPRD)体格检查所见的反流体征评估-10(RSA-10)。从两家欧洲医院连续纳入55例经下咽喉-食管多通道腔内阻抗-pH监测诊断的LPRD患者和115例无症状个体,评估内部效度、重测信度、内部一致性、聚合效度、评定者间信度及治疗反应性。结果显示RSA-10具有较高的内部一致性信度(α=0.822)和重测信度(rs=0.725),患者RSA-10评分显著高于对照组(p=0.001),与反流体征评分(RFS)显著相关(rs=0.771),评定者间信度良好(k=0.708),治疗后3个月较基线显著改善(p=0.001)。RSA-10>13可能提示LPRD,其与反流症状评分-12>11联合应用的敏感度为92.7%、特异度为97.3%。结论认为RSA-10是记录LPRD相关最常见喉部及喉外体征的可靠且有效的临床工具。
要点
- RSA-10内部一致性信度α=0.822,重测信度rs=0.725,评定者间信度k=0.708。
- 患者RSA-10评分显著高于对照组(p=0.001),与RFS显著相关(rs=0.771)。
- RSA-10>13可能提示LPRD,联合反流症状评分-12>11时敏感度92.7%、特异度97.3%。
核心结论
- RSA-10是记录LPRD相关最常见喉部及喉外体征的可靠且有效的临床工具。
研究设计与样本
- 从两家欧洲医院连续纳入经下咽喉-食管多通道腔内阻抗-pH监测诊断的LPRD患者及无症状个体,由三名有经验的耳鼻咽喉科医生进行RSA-10评分。
- 55例患者完成治疗前后评估(2020年1月至2023年12月),115例无症状个体完成研究。
- 评估内部效度、重测信度(7天内)、内部一致性(Cronbach's α)、聚合效度(与RFS相关性)、评定者间信度(Fleiss kappa)、治疗反应性及ROC分析阈值。
主要发现
- RSA-10具有较高的内部一致性信度(α=0.822)和重测信度(rs=0.725)。
- 患者RSA-10评分显著高于对照组(p=0.001),提示较高的内部效度。
- RSA-10与RFS显著相关(rs=0.771)。
- RSA-10子评分和总分的评定者间信度良好(k=0.708)。
- RSA-10从基线至治疗后3个月显著改善(p=0.001)。
关键数值与推荐
- RSA-10>13可能提示LPRD。
- RSA-10>13且反流症状评分-12>11与敏感度92.7%和特异度97.3%相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and validate the Reflux Sign Assessment-10 (RSA-10) for documenting the physical findings of laryngopharyngeal reflux disease (LPRD). METHODS: Patients with LPRD at the hypopharyngeal-esophageal multichannel intraluminal impedance-pH monitoring and asymptomatic individuals were consecutively recruited from two European hospitals. Three experienced otolaryngologists rated RSA-10 in patients and controls for assessing internal validity. RSA-10 was rated within a 7-day period to assess test-retest reliability. Internal consistency was measured using Cronbach's α in patients and controls. Convergent validity was evaluated through a correlation analysis between RSA-10 and Reflux Finding Score (RFS). Interrater reliability was evaluated by comparing the RSA-10 evaluations of the three otolaryngologists through Fleiss kappa. Pre- to posttreatment change of RSA-10 was evaluated to assess responsiveness to change. The RSA-10 thresholds were examined by receiver operating characteristic analysis. RESULTS: Fifty-five patients completed the pre- to posttreatment evaluations from January 2020 to December 2023. A total of 115 asymptomatic individuals completed the study. RSA-10 reported high internal consistency reliability (α = 0.822) and test-retest reliability (rs = 0.725). The RSA-10 scores of patients were significantly higher than those of controls (p = 0.001), suggesting high internal validity. RSA-10 was significantly correlated with the RFS (rs = 0.771). The interrater reliability was adequate for sub- and total RSA-10 scores (k = 0.708). RSA-10 significantly improved from baseline to 3-month posttreatment (p = 0.001). An RSA-10 > 13 may be suggestive of LPRD. Both RSA-10 > 13 and Reflux Symptom Score-12 > 11 were associated with a sensitivity of 92.7% and a specificity of 97.3%. CONCLUSION: The RSA-10 is a reliable and valid clinical instrument for documenting the most prevalent laryngeal and extra-laryngeal findings associated with LPRD. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:3981-3988, 2024.
引用
- Lechien JR, De Marrez LG, Finck C, et al. Validity and Reliability of the Reflux Sign Assessment-10 (RSA-10). Laryngoscope. 2024. PMID: 38551328. doi:10.1002/lary.31420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。